Is There a Guilt to Written Up Trial for TKD?

I'll narrow this one down to the AML 19 trial dealing with fit younger patients with high risk AML or MDS so these are patients who have bad prognosis based on chromosomes and or molecular studies. They compared what they consider their standard induction regimen which is flag ida to liposomal encapsulated donor ribousinsiderabine, developmentally called CPX351. The overall results of the trial did not show a benefit for either of these agents over the other but as always and you can see the survival is more encouraging in this bad group of patients because many of them have had P53 mutations. I don't think it'll be possible to discern a difference unless you do